Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Good video. IMO that is not why we continue our pps increase. He is speaking about gene therapy not stem cell treatments. Nothing to do with ACTCD
Good stuff. Only thing that can explain this are IMO Nasdaq up list, TLD, or financing agreement.
739,300 on the bid.
TLD or Nasdaq this week... IMO, it's gotta be.
Interesting pop, pre power hour.
3 months after final data collection puts the expected time frame release at sometime this month, September. IMO
The released the 6 month data results 3 months after collection. That is where I get the 3 month wait time frame from.
The word is still "getting around".
http://www.ag-ip-news.com/news.aspx?id=35271&lang=en
No one has surpassed ACTC "in this area"
And the reason they cannot invest yet (the referenced) is because we are not on a major exchange.... Yet.
“Completing this reverse stock split is an important step in our plan to improve our corporate structure and establish ACT as a highly-regarded, publicly-traded biotechnology company. With continued progress in many of our clinical and pre-clinical programs, the Lincoln Park equity facility in place and Dr. Wotton’s arrival as CEO, this initiative is part of a larger strategy to up-list to a national stock exchange and to raise awareness and visibility with fundamental-based, institutional biotech investors,” said Ted Myles, ACT’s Chief Financial Officer and Chief Operating Officer.
http://ir.advancedcell.com/press-releases/detail/2564/advanced-cell-technology-announces-1-100-reverse-stock-split
This would be almost perfect. Like going from 20/400 to 20/40.
ACT Confirms Clinical Trial Participant Showed Improvement in Vision from 20/400 to 20/40 Following Treatment
http://ir.advancedcell.com/press-releases/detail/674/act-confirms-clinical-trial-participant-showed-improvement
We're not a start up... But were about to start up phase 2 on the only FDA approved embryonic stem cell trial!!
“The addition of this new patent continues to strengthen our IP position around core cell therapy components and helps protect our leading position in the regenerative medicine field,” said Paul K. Wotton, Ph.D., President and Chief Executive Officer. “It is an exciting time to be here as we concentrate our efforts on developing cures for diseases and disorders of the eye and get ready to initiate phase 2 clinical trials for the treatment of Stargardt’s macular degeneration (SMD) and age-related macular degeneration (AMD).”
http://ir.advancedcell.com/press-releases/detail/2584/advanced-cell-technology-announces-issuance-of-patent
January?!? That's old news!!! Here's some real NEWS!!
http://ir.advancedcell.com/press-releases/detail/2574/distinguished-scientists-join-advanced-cell-technologys
http://ir.advancedcell.com/press-releases/detail/2584
Over 1 million on the bid.
10,900 on the bid at 8.85
Yeah GS, something of substantial significance is hopefully being worked on. Either way, we can be sure throughout the silence that BioHearts business plan is still in the works and revenue is coming in. IMO
Looks like it'll be a green day today, nothing too crazy obviously but... Still waiting on news about financing or phase 1 adipocell.
Compare the last 10Q to the previous ones. Progress and Growth is what you will see!!!
BIOHEART RELEASES Q2 FINANCIAL INFORMATION SHOWING GROWTH ________________________________________________________________________
Sunrise, Fla – August 7, 2014 – Bioheart, Inc. (BHRT.OB) released today financial information based on results from Q2 2014. The financial data shows that Bioheart has grown in product revenues, increased income, reduced debt, and further strengthened the financial standing of the company.
Bioheart product revenues are up from $24,321 to $819,606 comparing YTD 2013 to YTD 2014. The revenues recognized to date are related to sales of MyoCath, patient treatments, AdipoCell systems and related supplies, and cell culturing and banking services. Bioheart’s YTD net income increased to $226,034, as compared to a net loss of $1,269,231 in YTD 2013, primarily resulting from gain on settlement of debt.
“The financial backbone of Bioheart is getting stronger and we continue to make strides on a daily basis,” said Mike Tomas, Bioheart's president and CEO. “We have experienced two very strong quarters this year and will try to continue to improve
the well-being of Bioheart for our shareholders.”
Bioheart has continued to take steps to streamline operational costs, decreasing its net cash used in operating activities by 54% from $1,095,000 in YTD 2013 down to $507,000 in YTD 2014. Bioheart has been focused on reducing debt and decreasing current liabilities by $3.6 million (27%) from the beginning of the year. In addition, Bioheart has made strides to improve its working capital deficiency, decreasing the deficit by 28% from the beginning of the year.
The Financial Accounting Standards Board (FASB) issued an Accounting Standards Update (ASU) that restructures financial reporting for development stage entities by eliminating development stage reporting. Bioheart, as well as all entities in a development stage, will no longer need to present inception-to-date statements of operations or cash flows.
Here's the real story of BioHeart's business plan unfolding perfectly.
http://www.bioheartinc.com/News-Events/NewsReleases
8/7/2014
BIOHEART RELEASES Q2 FINANCIAL INFORMATION SHOWING GROWTH
7/24/2014
BIOHEART ANNOUNCES WORLD’S FIRST COMBINATION STEM CELL TREATMENT
7/16/2014
BIOHEART ANNOUNCES GRAND OPENING OF MAGNUM CELL THERAPIES
7/7/2014
BIOHEART ANNOUNCES CLINICAL TRIALS IN INDIA
BIOHEART ANNOUNCES JOINT VENTURE IN SOUTH AFRICA
6/4/2014
BIOHEART TO PRESENT AT THE PRP AND REGENERATIVE MEDICINE SYMPOSIUM
5/16/2014
BIOHEART TO PRESENT AT THE WORLD STEM CELLS & REGENERATIVE MEDICINE CONGRESS
5/15/2014
BIOHEART, INC. REPORTS SIGNIFICANT REVENUE INCREASES
5/13/2014
BIOHEART TO PRESENT AT 22ND MEDITERRANEAN CONFERENCE OF MEDICINE AND THERAPEUTIC COSMETIC SURGERY
5/5/2014
BIOHEART, INC. ANNOUNCES UPDATE ON PHASE I ADIPOSE STEM CELL TRIAL
4/30/2014
BIOHEART, INC. PRESENTED CLINICAL TRIAL RESULTS AT THE AGE MANAGEMENT MEDICINE GROUP CONFERENCE
4/23/2014
BIOHEART ANNOUNCES CLINICAL STUDY FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE
4/22/2014
BIOHEART, INC. TO PRESENT CLINICAL TRIAL RESULTS AT THE AGE MANAGEMENT MEDICINE GROUP CONFERENCE
4/2/2014
BIOHEART TO PRESENT AT SELECTBIO CLINICAL TRANSLATION OF STEM CELLS
3/26/2014
BIOHEART ANNOUNCES CLINICAL STUDY FOR DEGENERATIVE DISC DISEASE
3/25/2014
BIOHEART, INC. ANNOUNCES MIKE TOMÁS, PRESIDENT/CEO, HAS BEEN CHOOSEN AS AN HONOREE FOR EMERGE AMERICAS TECHWEEK100 MIAMI 2014
3/21/2014
BIOHEART, INC. TO PRESENT AT THE AMERICAN ASSOCIATION OF ORTHOPEDIC MEDICINE ON CELL THERAPY
3/17/2014
BIOHEART ANNOUNCES JOINT VENTURE WITH MAGNUM CELL THERAPIES
3/4/2014
BIOHEART ANNOUNCES POSITIVE 6 MONTH DATA FROM ANGEL PHASE I TRIAL
2/21/2014
BIOHEART REPORTS POSITIVE UPDATE ON CEO MIKE TOMÁS
1/29/2014
BIOHEART ANNOUNCES FIRST ADIPOSE DERIVED STEM CELL IMPLANTATION IN AZERBAIJAN
1/22/2014
BIOHEART ANNOUNCES EXCLUSIVE LICENSE IN VETERINARY MEDICINE FOR PATENTS FOR CANCER RELATED IMMUNOTHERAPY PRODUCTS
1/13/2014
BIOHEART, INC. TO PRESENT AT AMERICAN ACADEMY OF COSMETIC SURGERY
Haha... Going out of business?? The last PR tells a significantly different story!! Where are your facts?? Your statements are not backed by anything except who knows what....
http://www.bioheartinc.com/assets/press/BIOHEARTRELEASESQ2FINANCIALINFORMATIONSHOWINGGROWTH.pdf
BIOHEART RELEASES Q2 FINANCIAL INFORMATION SHOWING GROWTH ________________________________________________________________________
Sunrise, Fla – August 7, 2014 – Bioheart, Inc. (BHRT.OB) released today financial information based on results from Q2 2014. The financial data shows that Bioheart has grown in product revenues, increased income, reduced debt, and further strengthened the financial standing of the company.
Bioheart product revenues are up from $24,321 to $819,606 comparing YTD 2013 to YTD 2014. The revenues recognized to date are related to sales of MyoCath, patient treatments, AdipoCell systems and related supplies, and cell culturing and banking services. Bioheart’s YTD net income increased to $226,034, as compared to a net loss of $1,269,231 in YTD 2013, primarily resulting from gain on settlement of debt.
“The financial backbone of Bioheart is getting stronger and we continue to make strides on a daily basis,” said Mike Tomas, Bioheart's president and CEO. “We have experienced two very strong quarters this year and will try to continue to improve
the well-being of Bioheart for our shareholders.”
Bioheart has continued to take steps to streamline operational costs, decreasing its net cash used in operating activities by 54% from $1,095,000 in YTD 2013 down to $507,000 in YTD 2014. Bioheart has been focused on reducing debt and decreasing current liabilities by $3.6 million (27%) from the beginning of the year. In addition, Bioheart has made strides to improve its working capital deficiency, decreasing the deficit by 28% from the beginning of the year.
The Financial Accounting Standards Board (FASB) issued an Accounting Standards Update (ASU) that restructures financial reporting for development stage entities by eliminating development stage reporting. Bioheart, as well as all entities in a development stage, will no longer need to present inception-to-date statements of operations or cash flows.
That asking price should be raised.
Nice volume today. News coming??
Run forest!!
Excellent.
There it is! I hadn't even noticed a link at the bottom. I always use the top right.
Strange... Wish I had a different way of proving it. Both on my iPhone and iPad the "blog" sends me to where I'm stating the CSO blog is now. It used to give me that error for stemcellceo but now it's a page on investorstemcell that it sends me to.
Exactly what I Was thinking thinking, prepping for a new blog. IMO
GS I just tried it. I went to the bioheartinc.com website. Clicked on the "blog" link and it shot me straight to http://investorstemcell.com/author/bioheart/ where the uploaded the CSO blog.
Recent Blog.
Greetings,
Kristin Comella
Chief Scientific Officer
The field of regenerative medicine is rapidly developing new therapies to offer hope to patients who previously had very limited options. Bioheart, founded in 1999, has been at the forefront of these developments for over 15 years. We treated our first human patient in 2001 with muscle stem cells, or myoblasts.
Our product, MyoCell, has been the subject of nearly a dozen peer reviewed journal articles and has been reported on by many prominent speakers. The results of the MARVEL trial speak for themselves. In the double blind placebo controlled MARVEL trial, myoblast treated patients increased in exercise capacity by 95.6 meters while control patients declined by 3.6 meters after 6 months. This is double the improvement that was reported by others in autologous bone marrow and cardiac stem cells trials and more than eight times better than results published in allogeneic bone marrow studies. We are continuing to study this therapy in double blind placebo trials including MARVEL part 2 and MIRROR. We intend to continue the placebo trials including MARVEL part 2 and MIRROR—and continued enrollment in placebo trials including MARVEL part 2 and MIRROR studies is dependent on obtaining the necessary funding. Because they are double blind placebo controlled studies, results will only be presented after enrollment is complete.
Since its inception, Bioheart has striven to break new ground in regenerative medicine and had published many “firsts” for the field. We were the first company to gain approval from the FDA for a phase I study for a combined cell and gene therapy product for congestive heart failure patients. This type of therapy truly defines the world of regenerative medicine where we combine different modalities of regeneration to reverse the effects of disease and aging.
Approximately 7 years ago, our team began working with adipose derived stem cells (ADSCs) and currently market this product under the name AdipoCell™. We have completed a variety of animal studies to demonstrate that the cells can engraft and promote healing. ADSCs have the ability to increase angiogenesis or formation of blood vessels which makes this therapy appropriate for a variety of degenerative diseases with ischemic tissue. The cells are naturally anti-inflammatory and can suppress an over reactive immune system.
Since that time, together with our team of physician collaborators, we have completed over 3500 patients for a variety of conditions. We are currently working with the Global Stem Cell Group and Stem Cell Training Inc. to train physicians on these therapies for use in their clinic. We are currently studying the use of AdipoCell in the following applications: osteoarthritis, rheumatoid arthritis, degenerative disc disease, COPD, diabetes, erectile dysfunction, heart disease, critical limb ischemia, and more. In fact, we have recently received approval for several IRB studies which are listed on www.clinicaltrials.gov. We feel that it is important to gather important safety and efficacy data to fully understand the expected outcomes with these therapies.
We recently released the preliminary 6 month data from our phase I ANGEL Trial. Fully funded by Bioheart, the trial is being conducted in Mexico at the Hospital Angeles in conjunction with the Regenerative Medicine Institute (RMI). This phase I study will provide necessary safety and preliminary efficacy of AdipoCell in patients with congestive heart failure. Endpoints include safety, exercise capacity, quality of life, and ejection fraction at 3 months, 6 months and 12 months.
At the 6 month time point, patients are demonstrating an average improvement in exercise capacity or a six minute walk test of approximately 68 meters as compared to an average improvement of 47 meters at 3 months. Eighty percent of the patients showed an improvement in their exercise capacity from 3 months to 6 months post stem cell injection.
Another end point in the study is ejection fraction (EF) by echocardiogram. At the 3 month time point, 100% of the patients demonstrated either improvement or stayed the same. After 3 months, patients showed an average absolute improvement of 3 percentage points in ejection fraction. The patients continued to improve from 3 months to 6 months with a statistically significant average absolute improvement of 10 percentage points (p=0.01). I will present the full six month data at the upcoming Age Management Medicine Group conference in Orlando on April 25th (www.agemed.org).
Another service that we offer to our network of physicians is stem cell banking. We are a registered FDA tissue bank and can process, culture expand and cryopreserve tissue for interested patients. We are working with several hundred physicians who are currently making these services available to their patients. We are able to bank stem cells from fat, bone marrow and cord blood. We work with several clinics outside the US so that patients may receive these banked doses including two in Mexico, Jamaica, and Honduras.
One of our newest projects is cellular based immunotherapy. Cellular based immunotherapy is a method to help a patient’s immune system recognize and stop cancer. Bioheart has entered into an exclusive agreement to license three different cellular based immunotherapy patents from inventor Allan Wu, M.D. Dr. Wu has invented a method of immunotherapy for the treatment of malignant tissues using a unique mixed population of cells and antigen sources. Animal studies in dogs are underway. We have successfully completed the first set of experiments using canine cells and we are now beginning to dose those animals. We are expecting results on this project later this year. If successful, we will offer a new solution to dogs who are suffering from terminal cancers.
Our team at Bioheart is constantly working to advance the field of Regenerative Medicine. As a small start-up company, our team can remain focused on bringing the newest therapies to patients without the hindrances of big company bureaucracy. We are bringing the latest techniques to the clinic to help defeat some of the toughest diseases.
Feel free to email me directly with any questions about our research or current projects.
Warm regards.
Kristin Comella
Chief Scientific Officer
- See more at: http://investorstemcell.com/ceo-blogs/bioheart-cso-update/#sthash.U0h7WW3c.dpuf
BioHeart changed the "blog" link on their website, it now directs you to the new place where future blogs will be put. Stemcellceo is no longer working. You can also read our CSOs blog that was the final blog uploaded to stemcellceo.
Here's the link.
http://investorstemcell.com/author/bioheart/
Here come the EOD fireworks.
A clue off of BHRTs twitter
https://mobile.twitter.com/BioheartInc
ACTCD's work is mentioned here... Without mentioning ACTCD.
http://www.opticianonline.net/towards-2020-eye-treatment-future/
I agree 100%. We've held above .02 for a very long time now since our sub .01 days. Business plan unfolding perfectly IMO and I'll take a gradual increase over a one day explosion that doesn't hold. We've held above 150% increase YTD. More to come IMO.
Haha regenerative ice!
Relax... It was just a sale. All it has to do is sell at a higher price than what it sold for when you called it a "dump" and viola! There will be a "jump".
How are you feeling? Green or red tomorrow? I can't tell... A RS by itself to me means Red unless share holders remember the bigger picture of the TLD and up list... Green if tomorrow we get some sort of catalyst PR. I don't think we can be sure about NEJM not including TLD tomorrow regardless of the people who receive the NEJM in advance because I believe that since that information is so sensitive to being inside information they cannot risk allowing some to get the info before others... IMO it could still be in the NEJM tomorrow. But... I've always felt that the company would be better off up listing before releasing the TLD.